C5 Biosimilar Antibody

CH 7092230 research-grade biosimilar; CH-7092230 research-grade biosimilar; Complement c5 inhibitory humanized recycling monoclonal antibody (rg-6107) research-grade biosimilar; Crovalimab research-grade biosimilar; Crovalimab (genetical recombination) (JAN) research-grade biosimilar; Crovalimab (USAN/INN) research-grade biosimilar; CROVALIMAB-AKKZ research-grade biosimilar; Immunoglobulin g1, anti- (human complement c5) (humanized ro7112689 heavy chain), disulfide with humanized ro7112689 light chain, dimer research-grade biosimilar; Piasky research-grade biosimilar; RG 6107 research-grade biosimilar; RG-6107 research-grade biosimilar; RO 7092230 research-grade biosimilar; RO-7092230 research-grade biosimilar; RO-7112689 research-grade biosimilar; RO7112689/F01 research-grade biosimilar; RO-7112689/F01 research-grade biosimilar; RO711269 research-grade biosimilar; SKY59 research-grade biosimilar; SKY-59 research-grade biosimilar ; C5 antibody; CPAMD4 antibody; Complement C5 antibody; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4 [Cleaved into: Complement C5 beta chain antibody; Complement C5 alpha chain antibody; C5a anaphylatoxin antibody; Complement C5b antibody; Complement C5 alpha' chain] antibody